Heidelberg University

University of Minnesota Medical School

Physician-Scientist - Member of ASCI "Young Turks"

AresMIT Biomedical Computational Strategies (A.B.C.S)

Head of Strategy for Clinical Development and Translational Hematology-Oncology

Ares Pharmaceuticals, LLC

Head of Immuno-Oncology and Chief Medical/Chief Scientific Officer;

Oncotelic

Chief Medical Officer/Advisor

As a consultant to the Aptevo leadership, Dr. Uckun provides subject matter expertise in design of patient-centric clinical trials in acute leukemia patients.  In collaboration with other leukemia experts at academic health centers in the US and Europe, he contributes to the design of clinical research protocols to evaluate Aptevo's bispecific antibodies as components of innovative multi-modality regimens that may improve the outcome of adult and pediatric acute leukemia patients.

Aptevo Therapeutics Inc

Consultant; Chief Clinical Advisor

As Executive Vice President, Clinical Affairs,  Global Head of Clinical and Medical Affairs, and Chief Scientific Officer,  Dr. Uckun’s  responsibilities include providing medical-scientific leadership and direction for Reven’s pipeline of clinical development programs in sepsis, metabolic disorders, inflammatory disorders, including but not limited to non-alcoholic fatty liver disease and non-alcoholic steatohepatitis (NASH), iatrogenic organ toxicity, including chemotherapy-induced liver toxicity, and translational oncology as well as contributing to the strategy, direction and execution of the company's clinical development plans. Dr. Uckun will coordinate collaborations with academic centers and other biotech and pharmaceutical companies and provide day-to-day oversight for internal research, research and development, regulatory, safety as well as clinical operations teams.

Reven Pharmaceuticals

Exec Vice President, Global Head of Clinical and Medical Affairs; Chief Medical & Scientific Officer

Worldwide Clinical Trials

Vice President and Clinical Strategy Lead, Oncology-Hematology, Member of COVID-19 Task Force

Oncotelic, Inc.

Chief Medical Officer

In April 2019. Mateon Therapeutics, Inc. (OTCQB:MATN) and Oncotelic Inc.  have completed their  merger and created a new immuno-oncology company with a late-stage clinical asset against cancer and a promising product pipeline. 

In connection with the merger, Oncotelic, Inc. has become a wholly owned subsidiary of Mateon, with the former Oncotelic shareholders receiving a combination of common and preferred stock in Mateon representing approximately 85% of Mateon’s outstanding equity. Mateon’s prior stockholders retain approximately 15% of the outstanding equity.

Mateon Therapeutics

Function as a senior strategy advisor  in Clinical Development, Global Oncology and Hematology with an emphasis on advanced solid tumors and relapsed or therapy-refractory hematologic malignancies

Contribute to design of clinical path for small molecules as well as biologics with an emphasis on immuno-oncology drugs.  

Contribute to regulatory strategy for clinical development of multiple drug candidates, including targeted therapeutics, therapeutic vaccines, immuno-modulators, cytotoxic agents, immuno-oncology drugs. 

Contribute to biomarker identification and design of biomarker-guided clinical trials

https://www.syneoshealth.com/

Syneos Health (Previously INC Research/inVentiv Health)

Executive Medical Director, Global Oncology & Hematology

University of Southern California

Principal Investigator; USC Stem Cell Regenerative Medicine Initiative

Member, Norris Comprehensive Cancer Center

Professor of Research Pediatrics, Department of Pediatrics at USC Keck School of Medicine

Member, Developmental Therapeutics Program, Norris Comprehensive Cancer Center

Professor

Professor Research Pediatrics
Head, Translational Research in Leukemia and Lymphoma

Children's Hospital Los Angeles CHLA

Professor Research Pediatrics and Head, Translational Research in Leukemia and Lymphoma at the CCCBD

Coordinated target validation, portfolio prioritization, and drug discovery/development efforts in oncology and infectious diseases.

Paradigm Pharmaceuticals LLC

President/CSO

A 501(c)3 research organization that was formed to discover new drug candidates against cancer. Spin off companies included Alexander Parker Corporation, Paradigm Pharmaceuticals, Jupiter Research.

Drug Discovery Enterprises (dba Parker Hughes Institute)

Director, Research (also served as the founding President/CEO of its spin-off biotech companies)

Coordinated the CRO function of the company for the Drug Discovery Enterprises, Inc(dba Parker Hughes Institute). Served as the lead FDA contact and IND Investigator-Sponsor for Phase 1, Phase 2 and randomized Phase 2 clinical trials of immuno-oncology products. Served as the lead contact for the Childrens Cancer Study Group for groupwide clinical testing of anti-CD19 immunoconjugates.

Select references:
Seibel NL, Sather H, Steinherz PG, De Laat C, Ettinger LJ, Freyer D, et al. Upfront treatment with B43 PAP immunotoxin in newly diagnosed children with higher risk ALL. Children's Cancer Group. Blood. 1961;2000;96:721a.

Seibel NL, Krailo M, O'Neill K, Franklin J, Uckun F, Reaman GH. Phase I study of B43-PAP immunotoxin in combination with standard 4-drug induction for patients with CD19+ acute lymphoblastic leukemia (ALL) in relapse, a Children's Cancer Group Study. Pediatric Research. 1999;45:5. Abstract 195.

Alexander Parker Corporation

Directed translational biotherapy research on immunoconjugates, monoclonal antibodies, fusion toxins, and cytokine-drug conjugates. Reported to Provost of Academic Health Center and coordinated clinical and laboratory research efforts funded by multiple NIH grants.

Fatih M. Uckun, M.D., Ph.D